CIK 0001501697
- Non-accelerated filer
- Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273181608
- Phone
- +1 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +328,909 | 600,672 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +114,320 | 714,992 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +653,974 | 1,368,966 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion | +500,000 | $10.00 | $5.0M | 1,868,966 |
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series A-1 Convertible Preferred Stock | −66,667 | 0 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series A-2 Convertible Preferred Stock | −704,846 | 0 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series B Convertible Preferred Stock | −736,648 | 0 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series C Convertible Preferred Stock | −229,412 | 0 | ||
| 2017-11-20 | ORBIMED ADVISORS LLC 10% owner | Conversion · Series D Convertible Preferred Stock | −2,232,014 | 0 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion | +19,533 | 19,533 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion | +252,230 | 271,763 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion | +328,909 | 600,672 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion | +114,320 | 714,992 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion | +653,974 | 1,368,966 | ||
| 2017-11-20 | GORDON CARL L Director | Purchase | +500,000 | $10.00 | $5.0M | 1,868,966 |
| 2017-11-20 | GORDON CARL L Director | Conversion · Series A-1 Convertible Preferred Stock | −66,667 | 0 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion · Series A-2 Convertible Preferred Stock | −704,846 | 0 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion · Series B Convertible Preferred Stock | −736,648 | 0 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion · Series C Convertible Preferred Stock | −229,412 | 0 | ||
| 2017-11-20 | GORDON CARL L Director | Conversion · Series D Convertible Preferred Stock | −2,232,014 | 0 |
Page 20 of 25 · 490 trades